Montelukast IR Tablets and Chewable Tablets are part of an ever-growing portfolio that Ajanta Pharma has developed for the US market.
Ajanta Pharma USA Inc., a subsidiary of Ajanta Pharma Limited, announced today the launch of Montelukast Sodium IR Tablets (10mg) and Montelukast Sodium Chewable Tablets (4mg & 5mg), generic versions of SINGULAIR Tablets and SINGULAIR Chewable Tablets, respectively. The United States Food & Drug Administration (US FDA) approval extends the breadth of the Montelukast offerings from Ajanta Pharma into three dosage forms (Immediate-Release Tablets, Chewable Tablets, and Oral Granules).
Montelukast IR Tablets and Chewable Tablets are part of an ever-growing portfolio that Ajanta Pharma has developed for the US market. To date, the US FDA has granted Ajanta Pharma five ANDA final approvals and two ANDA tentative approvals. An additional 19 ANDAs are pending approval from the US FDA.
The scrip opened at Rs. 1400 and has touched a high and low of Rs. 1405.95 and Rs. 1360 respectively. So far 242061(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 12119.53 crore.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1720 on 12-Aug-2015 and a 52 week low of Rs. 890 on 26-Dec-2014. Last one week high and low of the scrip stood at Rs. 1387.85 and Rs. 1318.8 respectively.
The promoters holding in the company stood at 73.78 % while Institutions and Non-Institutions held 9.66 % and 16.56 % respectively.
The stock is currently trading above its 100 DMA.
No comments:
Post a Comment